CHILDREN'S MOTRIN COLD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHILDREN'S MOTRIN COLD (CHILDREN'S MOTRIN COLD).
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. It provides analgesic, antipyretic, and anti-inflammatory effects. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
| Metabolism | Ibuprofen is primarily metabolized in the liver via CYP2C9 and CYP2C19. Pseudoephedrine is partially metabolized in the liver by N-demethylation and oxidative metabolism; about 55-75% excreted unchanged in urine. |
| Excretion | Renal: ibuprofen ~90% as metabolites and conjugates, <10% unchanged; pseudoephedrine ~70-90% unchanged renally; urinary pH influences pseudoephedrine elimination (acidic urine increases excretion). Fecal: negligible. |
| Half-life | Ibuprofen: 2-4 hours in children; pseudoephedrine: 5-8 hours (prolonged in alkaline urine). Clinical context: dosing intervals q6-8h for ibuprofen; pseudoephedrine accumulation possible with renal impairment. |
| Protein binding | Ibuprofen: >99% bound to albumin; pseudoephedrine: 10-20% bound to plasma proteins. |
| Volume of Distribution | Ibuprofen: 0.1-0.2 L/kg; pseudoephedrine: 2-3 L/kg (extensive tissue distribution). Clinical meaning: ibuprofen low Vd indicates confinement to vascular space; pseudoephedrine high Vd indicates wide distribution. |
| Bioavailability | Ibuprofen: oral ~80-100% (immediate release); pseudoephedrine: oral ~90%. |
| Onset of Action | Ibuprofen: oral ~30-60 minutes; pseudoephedrine: oral ~30 minutes for decongestant effect. |
| Duration of Action | Ibuprofen: 4-6 hours (antipyretic/analgesic); pseudoephedrine: 4-6 hours (decongestant). Note: duration may be shorter in children. |
Adults and children ≥12 years: 20 mL (400 mg ibuprofen/30 mg pseudoephedrine) orally every 4-6 hours as needed; maximum 80 mL (1600 mg ibuprofen/120 mg pseudoephedrine) per day.
| Dosage form | SUSPENSION |
| Renal impairment | eGFR ≥30 mL/min: No adjustment. eGFR 15-29 mL/min: Avoid use. eGFR <15 mL/min: Contraindicated. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution; reduce dose by 50%. Child-Pugh Class C: Avoid use. |
| Pediatric use | Children 6-11 years (20-43 kg): 10 mL (200 mg ibuprofen/15 mg pseudoephedrine) orally every 6-8 hours; maximum 40 mL per day. Children 2-5 years (10-20 kg): 5 mL (100 mg ibuprofen/7.5 mg pseudoephedrine) orally every 6-8 hours; maximum 20 mL per day. Avoid in children <2 years. |
| Geriatric use | Start at lower end of dosing range (e.g., 10 mL) due to increased risk of renal impairment, gastrointestinal bleeding, and cardiovascular events; maximum duration of 5 days for cold symptoms. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CHILDREN'S MOTRIN COLD (CHILDREN'S MOTRIN COLD).
| Breastfeeding | Ibuprofen: Limited excretion into breast milk (M/P ratio ~0.01); considered compatible with breastfeeding. Pseudoephedrine: Excreted into breast milk (M/P ratio ~2.5-3.5); may reduce milk production and cause irritability in infants; use with caution. Chlorpheniramine: Excreted in small amounts; may cause drowsiness in infants; use lowest effective dose. |
| Teratogenic Risk | First trimester: NSAIDs are associated with increased risk of miscarriage and cardiac defects; avoid. Second trimester: Use only if clearly needed; no major teratogenic effects reported. Third trimester: NSAIDs cause premature closure of ductus arteriosus, oligohydramnios, and pulmonary hypertension; contraindicated after 30 weeks gestation. |
■ FDA Black Box Warning
Cardiovascular thrombotic events: NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Gastrointestinal bleeding: NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
| Serious Effects |
Hypersensitivity to ibuprofen, pseudoephedrine, or any component; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; coronary artery bypass graft (CABG) surgery; active gastrointestinal bleeding or perforation; severe renal impairment; patients with severe hypertension or coronary artery disease; use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs.
| Precautions | Cardiovascular risk, gastrointestinal risk (bleeding, ulceration, perforation), hypertension, renal toxicity (especially in patients with preexisting renal disease), hepatic effects, serious skin reactions (e.g., Stevens-Johnson syndrome), masking signs of infection, caution in patients with asthma, pregnancy category C (avoid in third trimester), use with other NSAIDs or anticoagulants increases bleeding risk. |
Loading safety data…
| Fetal Monitoring | Monitor for oligohydramnios and ductus arteriosus constriction with prolonged NSAID use in second/third trimester. Assess fetal growth and amniotic fluid volume if used chronically. Monitor maternal blood pressure and renal function. Observe infant for drowsiness or irritability if pseudoephedrine/chlorpheniramine used near term. |
| Fertility Effects | Ibuprofen may reversibly impair ovulation by inhibiting prostaglandin synthesis; effects resolve upon discontinuation. No known effect on spermatogenesis. Pseudoephedrine and chlorpheniramine have no established impact on fertility. |
| Food/Dietary | Avoid alcohol while taking this medication. Ibuprofen may interact with caffeine, increasing GI irritation. Pseudoephedrine may be less effective if taken with acidic foods (e.g., citrus) due to altered absorption. No other significant food interactions. |
| Clinical Pearls | This combination product contains ibuprofen (NSAID) and pseudoephedrine (decongestant). Avoid in patients with hypertension, cardiovascular disease, or NSAID sensitivity. Ibuprofen may mask fever. Use with caution in pediatric patients due to risk of Reye's syndrome in viral illness (though risk primarily with aspirin). Monitor for excessive CNS stimulation from pseudoephedrine. |
| Patient Advice | Do not exceed recommended dose or duration of 5 days for fever or 10 days for pain. · Do not take with other products containing ibuprofen or other NSAIDs. · Avoid use if you have high blood pressure, heart disease, or are taking blood thinners. · Stop use and consult a doctor if symptoms worsen or new symptoms occur. · Keep out of reach of children; seek immediate medical attention in case of overdose. |